Rifampin makes Tofacitinib less effective. So use Isoniazid for latent Tb prophylaxis Also speaker describing using once a week Rifapentine (drug interaction not an issue due to dosing) - I’ve no experience with this #eular2019

Good news for kids with scleroderma. Large database showing stability of SSc over time in kids SAT0479. Inception cohort. Improvement to follow over longer time. #EULAR2019 @RheumNow https://t.co/oK4Ejr9PQW

Almost a 50% of RA women will not improve during pregnancy and rates increases up to 70% in AS. So be aware that meds will be necessary in many pregnant women. Nelson-Piercy at Win&Hot session #EULAR2019 @RheumNow

Do you routinely ask about vaccinations in your pts? FRI0658 #EULAR2019 @RheumNow

Dr. Kevin Winthrop at #EULAR2019 during his infection lecture delivers the Pearl that Tofacitinib pts found to have Latent TB cannot take Rifampin - drug interaction w/ Tofa (lowers levels) https://t.co/LpoRbVC77J

Baricitinib long term clinical trial safety up to 7yrs #EULAR2019 https://t.co/jFKOrS28wz

EULAR recommendations for the diagnosis and the management of rheumatic immune-related adverse events due to cancer immunotherapy #EULAR2019 https://t.co/azj3ZPOxqb

In women with SLE on MMF, switch to AZA and wait 3 months prior to trying to conceive as some will flare with the switch. Catherine Nelson-Piercy. #EULAR2019

Wellbeing measures in RA: a summary of Baracitinib vs Adalimumab #EULAR2019 https://t.co/0bYHLpzSrV

ACR CRISS shows efficacy in ASSET (abatacept) trial in scleroderma. Another trial with positive CRISS. #EULAR2019 POSTER FR0327. @bmsnews https://t.co/6dTdehoAUe

Dr Nelson-Piercy illustrates drugs that can & can't be used during pregnancy. Win&Hot session #EULAR2019 @RheumNow https://t.co/C9g8tyBixj

So many factors contribute to disease activity. The scatterplot’s got scatter: at least for SpA, adalimumab drug concentrations are at most only one of those factors. #EULAR2019 FRI0381 from Groningen @RheumNow https://t.co/SaWg143ViT

Busy day at Eular Madrid #EULAR2019 @RheumNow https://t.co/QB6vkbzvmW

Dr Alvin Wells - ACrossover Swithchiing study of the Jak inhibitor UPAdacitinib and adalimumab. OP0029. #EULAR2019 https://t.co/MqLtR8qmwJ

Dr. Atul Deodhar presents data showing that secukinumab treated ankylosing spondylitis patients respond better when treated early. #EULAR2019 FRI0388 https://t.co/7swe9vpRdl